The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes
Open accessAbstract
BACKGROUNDA previous phase I study showed that the infusion of autologous Tregs expanded ex vivo into patients with recent-onset type 1 diabetes (T1D) had an excellent safety profile. However, the majority of the infused Tregs were undetectable in the peripheral blood 3 months postinfusion (Treg-T1D trial). Therefore, we conducted a phase I study (TILT trial) combining polyclonal Tregs and low-dose IL-2, shown to enhance Treg survival and expansion, and assessed the impact over time on Treg populations and other immune cells.METHODSPatients with T1D were treated with a single infusion of autologous polyclonal Tregs followed by one or two 5-day courses of recombinant human low-dose IL-2 (ld-IL-2). Flow cytometry, cytometry by time of flight, and 10x Genomics single-cell RNA-Seq were used to follow the distinct immune cell populations' phenotypes over time.RESULTSMultiparametric analysis revealed that the combination therapy led to an increase in the number of infused and endogenous Tregs but also resulted in a substantial increase from baseline in a subset of activated NK, mucosal associated invariant T, and clonal CD8+ T cell populations.CONCLUSIONThese data support the hypothesis that ld-IL-2 expands exogenously administered Tregs but also can expand cytotoxic cells. These results have important implications for the use of a combination of ld-IL-2 and Tregs for the treatment of autoimmune diseases with preexisting active immunity.TRIAL REGISTRATIONClinicalTrials.gov NCT01210664 (Treg-T1D trial), NCT02772679 (TILT trial).FUNDINGSean N. Parker Autoimmune Research Laboratory Fund, National Center for Research Resources.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SCANPY: large-scale single-cell gene expression data analysis
Wolf, F. A., Angerer, P., & Theis, F. J. (2018) · Genome Biology · doi:10.1186/s13059-017-1382-0 · Cited by 8,881
A function for interleukin 2 in Foxp3-expressing regulatory T cells
Fontenot, J. D., Rasmussen, J. P., Gavin, M. A., & Rudensky, A. Y. (2005) · Nature Immunology · doi:10.1038/ni1263 · Cited by 1,819
Genetics, pathogenesis and clinical interventions in type 1 diabetes
Bluestone, J. A., Herold, K., & Eisenbarth, G. (2010) · Nature · doi:10.1038/nature08933 · Cited by 1,265
Self-citationMiller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254 · cited 2×
“The disease pathogenesis, which is influenced by genetic and environmental factors, is attributed to the loss of immune tolerance which results in the development and inadequate control of pathogenic auto-reactive T cells that recognize and destroy islet beta cells (1-3).”
BackgroundMethodMultiplexed droplet single-cell RNA-sequencing using natural genetic variation
Kang, H. M., Subramaniam, M., Targ, S., Nguyen, M., Maliskova, L., McCarthy, E., Wan, E., Wong, S., Byrnes, L., Lanata, C. M., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4042 · Cited by 1,101 · cited 5×
“Resulting VCF genotype files and single-cell RNA-Seq BAM files were used to run Demuxlet (31) with default parameters.”
MethodInfluentialSelf-citationType 1 diabetes immunotherapy using polyclonal regulatory T cells
Bluestone, J. A., Buckner, J. H., Fitch, M., Gitelman, S. E., Gupta, S., Hellerstein, M. K., Herold, K. C., Lares, A., Lee, M. R., Li, K., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad4134 · Cited by 1,033
Self-citationSystemic Immunity Is Required for Effective Cancer Immunotherapy
Spitzer, M. H., Carmi, Y., Reticker-Flynn, N. E., Kwek, S. S., Madhireddy, D., Martins, M. M., Gherardini, P. F., Prestwood, T. R., Chabon, J., Bendall, S. C., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.022 · Cited by 963 · cited 1×
“Data normalization was performed as previously described (58).”
MethodSelf-citationCentral Role of Defective Interleukin-2 Production in the Triggering of Islet Autoimmune Destruction
Tang, Q., Adams, J. Y., Penaranda, C., Melli, K., Piaggio, E., Sgouroudis, E., Piccirillo, C. A., Salomon, B. L., & Bluestone, J. A. (2008) · Immunity · doi:10.1016/j.immuni.2008.03.016 · Cited by 729
Self-citationZunder, E. R., Finck, R., Behbehani, G. K., Amir, E.-A. D., Krishnaswamy, S., Gonzalez, V. D., Lorang, C. G., Bjornson, Z., Spitzer, M. H., Bodenmiller, B., et al. (2015) · Nature Protocols · doi:10.1038/nprot.2015.020 · Cited by 596 · cited 1×
“After data collection, each condition was deconvoluted using a single-cell de-barcoding algorithm (60).”
MethodSelf-citationPlasticity of Human Regulatory T Cells in Healthy Subjects and Patients with Type 1 Diabetes
McClymont, S. A., Putnam, A. L., Lee, M. R., Esensten, J. H., Liu, W., Hulme, M. A., Hoffmüller, U., Baron, U., Olek, S., Bluestone, J. A., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003099 · Cited by 428
Self-citationDiscovery of stimulation-responsive immune enhancers with CRISPR activation
Simeonov, D. R., Gowen, B. G., Boontanrart, M., Roth, T. L., Gagnon, J. D., Mumbach, M. R., Satpathy, A. T., Lee, Y., Bray, N. L., Chan, A. Y., et al. (2017) · Nature · doi:10.1038/nature23875 · Cited by 297
Self-citationThe Prevalence of Type 1 Diabetes in the United States
Menke, A., Orchard, T. J., Imperatore, G., Bullard, K. M., Mayer-Davis, E., & Cowie, C. C. (2013) · Epidemiology · doi:10.1097/ede.0b013e31829ef01a · Cited by 144
Using GWAS to identify genetic predisposition in hepatic autoimmunity
Webb, G. J., & Hirschfield, G. M. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.08.016 · Cited by 108 · cited 1×
“suggested a genetic link to IL-2 deficiency in this autoimmune setting (13).”
Background
Cited by
Peiseler, M., Schwabe, R., Hampe, J., Kubes, P., Heikenwälder, M., & Tacke, F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.012 · Cited by 564
Engineering IL-2 for immunotherapy of autoimmunity and cancer
Hernandez, R., Põder, J., LaPorte, K. M., & Malek, T. R. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00680-w · Cited by 355
Song, Y., Li, J., & Wu, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01952-8 · Cited by 259
Breaking Boundaries: Chronic Diseases and the Frontiers of Immune Microenvironments
Li, G., Wan, Y., Jiao, A., Jiang, K., Cui, G., Tang, J., Yu, S., Hu, Z., Zhao, S., Yi, Z., et al. (2025) · Med Research · doi:10.1002/mdr2.70007 · Cited by 63
The liver as a central "hub" of the immune system: pathophysiological implications
Ronca, V., Gerussi, A., Collins, P., Parente, A., Oo, Y. H., & Invernizzi, P. (2025) · Physiological Reviews · doi:10.1152/physrev.00004.2023 · Cited by 59
Metadata
- Authors
- Dong, S., Hiam-Galvez, K. J., Mowery, C. T., Herold, K. C., Gitelman, S. E., Esensten, J. H., Liu, W., Lares, A. P., Leinbach, A. S., Lee, M., Nguyen, V., Tamaki, S. J., Tamaki, W., Tamaki, C. M., Mehdizadeh, M., Putnam, A. L., Spitzer, M. H., Ye, C. J., Tang, Q., & Bluestone, J. A.
- Venue
- JCI Insight
- Published
- 2021-09-22
- Volume
- 6
- Issue
- 18
- ISSN
- 2379-3708 (ISSN-L)
- OpenAlex
- W3183662835
- Cited by
- 222
- References
- 13
- FWCI
- 17.00
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.